Key facts
- This page summarizes Patrick Bilbo's Form 4 filing for Organogenesis Holdings Inc. (ORGO).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 21 Feb 2025, 17:54.
Patrick Bilbo - 19 Feb 2025 Form 4 Insider Report for Organogenesis Holdings Inc. (ORGO)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- ORGO
- Reported as of
- 19 Feb 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Feb 2025, 17:54:26 UTC
- Prior SEC filing
- 19 Feb 2025
- Next SEC filing
- 18 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ William R. Kolb, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Patrick Bilbo filed Form 4 for Organogenesis Holdings Inc. (ORGO) on 21 Feb 2025.
Change
- Previous filing in this sequence was filed on 19 Feb 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ORGO
transaction
Class A Common Stock
Award
- Transaction value
- $0
- Shares
- +184,136
- Change %
- +24%
- Price
- $0.000000
- Shares after
- 949,062
- Date
- 19 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ORGO
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +190,475
- Change %
- Price
- $0.000000
- Shares after
- 190,475
- Date
- 19 Feb 2025
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 190,475
- Exercise price
- $3.53
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2025.
Footnote F2
The option becomes exercisable in equal annual installments over four years beginning February 15, 2025.